Want to see TSE:QAI full AI Analyst Report?
Top Page
Predictmedix
(QAI)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.05
▲(165.00% Upside)
Action:Reiterated
Date:02/28/26
The score is driven primarily by very weak financial performance (minimal revenue, ongoing losses, negative free cash flow, and negative equity). Technical indicators are mixed but generally soft (negative MACD and price below key moving averages), and valuation is constrained by ongoing losses and no dividend support.
Positive Factors
Low reported debt
Near-zero reported debt provides structural financial flexibility relative to highly leveraged peers. Over the next 2–6 months this reduces insolvency risk, eases interest burdens, and increases optionality to raise capital or invest in product development without heavy fixed financing costs.
Negative Factors
Negative shareholders' equity
Deeply negative equity reflects cumulative losses and materially weakens the balance sheet. Over months this limits financial flexibility, can impair counterparty confidence, restricts access to traditional financing, and raises the likelihood of dilutive recapitalizations if revenues don't stabilize.
Read all positive and negative factors
Positive Factors
Negative Factors
Low reported debt
Near-zero reported debt provides structural financial flexibility relative to highly leveraged peers. Over the next 2–6 months this reduces insolvency risk, eases interest burdens, and increases optionality to raise capital or invest in product development without heavy fixed financing costs.
Read all positive factors
Predictmedix (QAI) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$6.57M
Dividend YieldN/A
Average Volume (3M)60.56K
Price to Earnings (P/E)―
Beta (1Y)0.21
Revenue GrowthN/A
EPS Growth23.08%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.00
Shares Outstanding219,087,540
10 Day Avg. Volume58,911
30 Day Avg. Volume60,565
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-1.71
Price to Sales (P/S)0.00
P/FCF Ratio-61.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Predictmedix Business Overview & Revenue Model
Company Description
Predictmedix Inc., an artificial intelligence (AI) company, develops AI powered technologies for general workplace health and safety, and health care industry. The company operates in two segments, Workplace Health and Safety, and Healthcare. It o...
How the Company Makes Money
null...
Predictmedix Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Predictmedix Technical Analysis
Neutral
0.02
Price Trends
0.03
Negative
0.04
Negative
0.05
Negative
Market Momentum
>-0.01
Negative
54.90
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:QAI, the sentiment is Neutral. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.05, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 54.90 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:QAI.
Predictmedix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$42.19M | -2.08 | -303.05% | ― | 35.27% | 58.34% | |
43 Neutral | C$17.36M | -6.87 | 56.40% | ― | 89.06% | 37.62% | |
42 Neutral | C$6.57M | -9.06 | 123.63% | ― | ― | 23.08% | |
41 Neutral | C$51.59M | -8.23 | -307.42% | ― | ― | -84.43% |
* Healthcare Sector Average
TSE:QAI
Predictmedix
0.03
-0.02
-33.33%
TSE:PINK
Perimeter Medical Imaging AI
0.27
0.03
12.77%
TSE:VPT
VentriPoint Diagnostics
0.09
-0.03
-21.74%
TSE:BLO
Cannabix Technologies
0.40
-0.14
-25.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.